On April 16, 2017 Genentech聽announced interim results聽from the Phase III HAVEN 2 study evaluating emicizumab prophylaxis in children聽less than 12 years of age with hemophilia A and inhibitors to factor VIII. According to this Genentech’s press releases, “interim analysis after a median of 12 weeks of treatment, emicizumab prophylaxis聽showed a clinically meaningful reduction in the number of bleeds over time.”

Read Genentech’s full press release regarding this data in it’s entirety.

Sign up for E-mails, Dateline Magazine, and other ways to stay connected.